Valuation: Pharmigene, Inc.

Market Cap 371M 11.5M 9.97M 9.34M 8.52M 16.01M 1.1B 16.26M 110M 42.93M 549M 43.18M 42.25M 1.83B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 941M 29.16M 25.27M 23.67M 21.59M 40.6M 2.78B 41.22M 278M 109M 1.39B 109M 107M 4.64B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day+2.08%
1 week+2.08%
Current month+4.85%
1 month+17.04%
3 months-26.50%
6 months-30.00%
Current year-25.76%
1 week 7.19
Extreme 7.19
7.36
1 month 5.9
Extreme 5.9
9.35
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
14.1
3 years 5.9
Extreme 5.9
24.6
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 2019-11-03
Chief Operating Officer 49 2019-11-03
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 35 2019-11-03
Director/Board Member 65 2020-08-06
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%+2.08%-37.97%-69.88% 11.27M
-0.55%+2.64%+99.45%+300.79% 4.05B
-3.73%-3.19%+55.30%+77.65% 3.73B
+3.85%+55.30%+202.24%-4.53% 2.94B
+0.17%+3.98%+279.70%+431.57% 2.44B
-2.25%+2.28%-22.78%-31.51% 2.35B
-3.75%+5.87%+9.27% - 1.35B
-1.84%+13.90%+17.46%+44.24% 1.05B
-0.52%-9.83%+114.87%-44.10% 866M
-1.62%+9.68%-36.81%-0.85% 572M
Average -0.82%+8.32%+68.07%+78.15% 1.94B
Weighted average by Cap. -0.93%+10.41%+100.30%+137.83%

Financials

2024 2025
Net sales 117M 3.61M 3.13M 2.93M 2.68M 5.03M 345M 5.11M 34.5M 13.49M 173M 13.57M 13.27M 575M 200M 6.2M 5.37M 5.03M 4.59M 8.63M 591M 8.76M 59.18M 23.13M 296M 23.27M 22.77M 987M
Net income -82.86M -2.57M -2.23M -2.09M -1.9M -3.58M -245M -3.63M -24.53M -9.59M -123M -9.65M -9.44M -409M -73M -2.26M -1.96M -1.84M -1.68M -3.15M -216M -3.2M -21.61M -8.45M -108M -8.5M -8.31M -360M
Net Debt 458M 14.2M 12.3M 11.52M 10.51M 19.76M 1.35B 20.07M 136M 52.98M 678M 53.3M 52.15M 2.26B 570M 17.66M 15.3M 14.34M 13.08M 24.59M 1.68B 24.96M 169M 65.92M 844M 66.32M 64.87M 2.81B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
26-08-12 NT$7.350 +2.08% 46,180
26-08-11 NT$7.200 0.00% 2,010
26-08-10 NT$7.200 0.00% 4,090
26-08-07 NT$7.200 0.00% 20
26-08-06 NT$7.200 0.00% 10
  1. Stock Market
  2. Stocks
  3. 7595 Stock